Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
The Denver II: A Major Revision and Restandardization of the Denver Developmental Screening Test
Countries citing papers authored by Howard Shapiro
Since
Specialization
Citations
This map shows the geographic impact of Howard Shapiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Shapiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Shapiro more than expected).
This network shows the impact of papers produced by Howard Shapiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Shapiro. The network helps show where Howard Shapiro may publish in the future.
Co-authorship network of co-authors of Howard Shapiro
This figure shows the co-authorship network connecting the top 25 collaborators of Howard Shapiro.
A scholar is included among the top collaborators of Howard Shapiro based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Howard Shapiro. Howard Shapiro is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Peden, Marc C., R. E. P. Frenkel, Howard Shapiro, & Ivaylo Stoilov. (2015). Visual acuity impairment under low luminance conditions at baseline is a powerful predictor of visual acuity response to ranibizumab therapy in patients with neovascular age-related macular degeneration. Investigative Ophthalmology & Visual Science. 56(7). 5362–5362.1 indexed citations
2.
Frenkel, R. E. P., Anne E. Fung, Howard Shapiro, & Ivaylo Stoilov. (2015). Low luminance vision improves nearly twice as much as standard vision with ranibizumab for neovascular age-related macular degeneration. Investigative Ophthalmology & Visual Science. 56(7). 5358–5358.1 indexed citations
3.
Dreyer, Richard F., et al.. (2013). Early vs Delayed 15-Letter Responders to Ranibizumab Treatment in Year 1 of the Phase III HARBOR Trial. Investigative Ophthalmology & Visual Science. 54(15). 3829–3829.1 indexed citations
Michels, Mark, Howard Shapiro, & Laura Wilson. (2008). Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): 2-Year Angiographic Results of PIER Study. Investigative Ophthalmology & Visual Science. 49(13). 2882–2882.1 indexed citations
11.
Rosenfeld, Philip J., et al.. (2008). Lesion Characteristics in Ranibizumab (LUCENTIS®) Treated Patients With a Visual Acuity (VA) Gain or Loss in the MARINA and ANCHOR Trials for Wet Age-Related Macular Degeneration (AMD). Investigative Ophthalmology & Visual Science. 49(13). 329–329.1 indexed citations
12.
Sadda, Srinivas R., Howard Shapiro, & S. Schneider. (2007). Anatomic Outcomes at 2 Years in the ANCHOR Study Comparing Ranibizumab (LucentisTM) and Verteporfin Photodynamic Therapy (PDT) in Predominantly Classic Neovascular Age-Related Macular Degeneration (AMD). Investigative Ophthalmology & Visual Science. 48(13). 4561–4561.1 indexed citations
13.
Rosenfeld, Philip J., et al.. (2007). Baseline and Treatment Characteristics of Patients Losing Vision at Year 1 of the MARINA and ANCHOR Trials. Investigative Ophthalmology & Visual Science. 48(13). 4576–4576.2 indexed citations
14.
Brown, David M., Howard Shapiro, & S. Schneider. (2006). Subgroup Analysis of First–Year Results of ANCHOR: A Phase III, Double–Masked, Randomized Comparison of Ranibizumab and Verteporfin Photodynamic Therapy for Predominantly Classic Choroidal Neovascularization Related to Age–Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 47(13). 2963–2963.6 indexed citations
Shapiro, Howard, et al.. (1980). Early effect of melanotropin on murine melanoma growth and cell cycle traverse in culture. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory).1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.